Search This Blog

Tuesday, March 31, 2020

Sorrento to test COVID-9 candidates in infection cell model with live virus

Sorrento Therapeutics (SRNE -1.4%) inks an agreement with the University of Texas Medical Branch (UTMB) at Galveston for the preclinical testing of its COVID-19 therapeutic candidates using an infection cell model for SARS-CoV-2. The testing will be conducted in a Biosafety Level 4 (maximum containment) laboratory at UTMB, one of only two on a university campus in the U.S., since it will be working with a COVID-19 viral isolate.
The company says it has a range of preclinical candidates across its platforms, including natural killer (NK) cell therapies, neutralizing antibodies (NAbs) and soluble recombinant fusion protein traps (COVIDTRAP) to potentially inhibit the binding of SARS-CoV-2’s spike protein with host ACE2 receptors on the surface of cells, thereby potentially preventing the first step in the infection process.
https://seekingalpha.com/news/3556953-sorrento-to-test-covidminus-9-candidates-in-infection-cell-model-live-virus

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.